Skip to main content

Table 4 14-3-3η levels by therapy group at baseline and after 1 year of therapy

From: Serum 14-3-3η level is associated with severity and clinical outcomes of rheumatoid arthritis, and its pretreatment level is predictive of DAS28 remission with tocilizumab

Group

Sample size

Pretreatment 14-3-3η

14-3-3η at 1 yr

p Value

Whole cohort

149

0.70 (0.17–5.96)

0.37 (0.11–1.82)

<0.0001

Adalimumab

49

0.62 (0.16–4.66)

0.38 (0.13–1.40)

<0.0001

Methotrexate

23

0.67 (0.17–1.89)

0.33 (0.11–1.44)

0.0101

Tocilizumab

50

0.43 (0.15–8.40)

0.27 (0.10–2.58)

0.0007

Tofacitinib

27

1.30 (0.21–9.46)

1.26 (0.11–3.07)

0.013

  1. Median (interquartile range) 14-3-3η serum titers at baseline and at 1 yr are compared with the whole cohort and each therapy group. Corresponding Wilcoxon matched-pairs signed-rank test values were calculated
Back to article page

Arthritis Research & Therapy

ISSN: 1478-6362

Contact us